logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Refractory or relapsed HL: ESHAOx displays modest activity, acceptable safety in phase 2

Korean trial finds that 33.3% showed a complete response; 38.9% a partial response.